Αποτελέσματα Αναζήτησης
The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...
8 Μαΐ 2023 · Procainamide is a medication used to manage and treat ventricular arrhythmias, supraventricular arrhythmias, atrial flutter, atrial fibrillation, AV nodal re-entrant tachycardia, and Wolf-Parkinson-White syndrome. It is a Class 1A antiarrhythmic agent.
For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.
3 Σεπ 2024 · Detailed Procainamide dosage information for adults and children. Includes dosages for Arrhythmias; plus renal, liver and dialysis adjustments. Skip to main content
20 Φεβ 2021 · Procainamide was administered within the scanner with intermittent intravenous boluses of 50 mg every minute until the complete suppression of PVCs up to a maximum dose of 10 mg/kg during continuous ECG monitoring and non-invasive blood pressure monitoring every minute.
1 Μαΐ 2017 · We performed a multicentre randomized open-labelled study to determine the safety and efficacy of intravenous procainamide and amiodarone for the acute treatment of tolerated wide QRS complex (probably ventricular) tachycardia.
Procainamide was more effective by 1.5 hours in those with AF than AFL/both: 46.3% vs 22.2% (P<0.01). All predictors except dose were associated with higher adjusted odds of cardioversion by 1.5 hours (Table).
